



**HOLD FOR RELEASE**  
June 27, 2008 – 8:00 AM EDT

**MARICAL ANNOUNCES EXCLUSIVE GLOBAL LICENSING OF ITS  
SUPERSMOLT<sup>®</sup> TECHNOLOGY TO EUROPHARMA.**

**Portland, Maine, USA** – MariCal CEO, Bruce Andrews announced today the exclusive global licensing of the Company’s smoltification technology, the SuperSmolt<sup>®</sup> Program, to Europharma to service the commercial salmon industry.

Europharma, the leading wholesaler and supplier of fish health products for the Norwegian fish farming industry, is owned by Nordly Holding AS based in Leknes, Norway. In addition to the Company’s Norwegian presence, currently supplying 70% of the aquaculture market with vaccine distribution, fish health products, feed, and services, the company also has established a significant presence in the Chilean salmon market through Europharma Chile since 2001.

MariCal and its Chilean subsidiary, CienciaMar, have offered the SuperSmolt<sup>®</sup> Program to the commercial salmon industry since 2002. MariCal initially established a relationship with one of Europharma’s sister companies, ACD Pharmaceuticals in 2006 for representation of the SuperSmolt<sup>®</sup> Program in the Norwegian market. “Given its strong market position, exceptional reputation for customer service and product support, and drive to expand and service the entire global commercial salmon industry, Europharma is the perfect strategic partner for MariCal” says William T. Thomas, MariCal’s COO.

“We have been searching for ways to establish Europharma in North America and the UK, and this was the opportunity we needed. It is an important step for Europharma and an excellent opportunity for gaining foothold in new markets”, says CEO Paal Christian Krüger of Europharma.

The SuperSmolt<sup>®</sup> Program permits a faster, more efficient way of pre-adapting smolt for seawater entry. The technology is currently being used commercially by fish farmers throughout the world.

“We have great belief in this product, and our two-year involvement in presenting the SuperSmolt<sup>®</sup> Program to the Norwegian fish farming industry has convinced us of its great potential worldwide. In addition, we are looking forward to closely working with MariCal and

their continued commitment to aquaculture R&D to further exploit their unique technology to the benefit of the salmon industry”, says Paal Christian Krüger.

Bruce Andrews expressed, “This transaction better aligns MariCal’s focus as an intellectual property developer of its Calcium Sensing Receptor (CaSR) technology with applications for aquatic, food and companion animals while supporting effective commercialization of the SuperSmolt® Program through Europharma as an industry leader.”

---

### **About MariCal:**

MariCal, headquartered in Portland, Maine was founded in 1996 and is a privately held animal health and nutrition biotechnology company with operations in Chile, through its subsidiary CienciaMar, and offices in Canada, United Kingdom, and Norway. In addition, MariCal is a joint-venture partner in Low Salinity Inc., based in Saltville, Virginia - a land-based recirculation production and research facility for cobia. MariCal is a recognized global leader in aquatic and terrestrial biotechnology possessing 49 issued and pending patents in their field. MariCal’s key discovery is that of a class of molecular extracellular ion receptor proteins, called Calcium Receptors (CaR’s), that serve as the biological “thermostats,” or “master switches” that enable fish and other aquatic organisms to sense and respond to changes in both water salinity and nutrients in their aquatic environment. Over the past 10 years, the Company has focused both its product development and licensing efforts in the fields of aquaculture, fisheries, and marine products. It now is starting to invest and develop use for the technology in terrestrial animals. (For more details on MariCal visit [www.marical.biz](http://www.marical.biz) ).

### **About Europharma:**

Europharma is the leading wholesaler and supplier of fish health products for the Norwegian fish farming industry. The company has been present in the Chilean market since 2001, and is currently in the process of establishing in the UK.

Europharma supplies the complete range of fish health products available for the fish farming industry, giving our customers the benefit of not having to rely on several different suppliers to handle their requirements.

In addition to always delivering ordered goods on time, Europharma ensures that storage and transportation is being carried out in a safe manner. Vaccines are temperature sensitive, and to ensure an unbroken chill chain Europharma has at its disposal a fleet of specially equipped vehicles that brings sensitive products all the way to the fish farming sites. Temperature data is continually registered through storage and transportation, securing the documentation needed to achieve a level of traceability that is now a growing market demand.

Fish farming success is always based on knowledge. The Europharma staff includes pharmacists, fish health biologists and veterinarians, and our competence is there for our customers to use. Producer independence makes Europharma a trustworthy partner and advisor in deciding the right solutions in terms of your specific fish health needs. (For more details on Europharma visit [www.europharma.no](http://www.europharma.no) ).

-END-

---

**For additional information on MariCal, please contact:**

William T. Thomas  
Chief Operating Officer  
MariCal  
400 Commercial Street  
Portland, Maine 04101 USA  
Office Phone: 207-773-2500  
Mobile: 207-756-2367

**For additional information on Europharma, please contact:**

Paal Christian Krüger  
CEO  
Europharma AS  
Lufthavnveien 3, 8370 Leknes,  
Norway  
Phone: +47 76 06 09 35  
Mobile: +47 95 45 36 20